Reply

Affiliations

¹ Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Clinical Trial and Research Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
² Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Clinical Trial and Research Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Electronic address: jfzhou@tjh.tjmu.edu.cn.

Comment

Yang Cao et al. J Allergy Clin Immunol. 2020 Dec.

. 2020 Dec;146(6):1453-1454.

doi: 10.1016/j.jaci.2020.07.037. Epub 2020 Sep 18.

¹ Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Clinical Trial and Research Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
² Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; Clinical Trial and Research Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Electronic address: jfzhou@tjh.tjmu.edu.cn.

No abstract available

Comment on

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.
Cao Y, Wei J, Zou L, Jiang T, Wang G, Chen L, Huang L, Meng F, Huang L, Wang N, Zhou X, Luo H, Mao Z, Chen X, Xie J, Liu J, Cheng H, Zhao J, Huang G, Wang W, Zhou J. Cao Y, et al. J Allergy Clin Immunol. 2020 Jul;146(1):137-146.e3. doi: 10.1016/j.jaci.2020.05.019. Epub 2020 May 26. J Allergy Clin Immunol. 2020. PMID: 32470486 Free PMC article. Clinical Trial.
Whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe COVID-19.
Li H, Liu H. Li H, et al. J Allergy Clin Immunol. 2020 Dec;146(6):1453. doi: 10.1016/j.jaci.2020.09.002. Epub 2020 Sep 17. J Allergy Clin Immunol. 2020. PMID: 32980157 Free PMC article. No abstract available.

1. Li H., Liu H. Whether the timing of patient randomization interferes with the assessment of the efficacy of Ruxolitinib for severe COVID-19. J Allergy Clin Immunol. 2020;146:1453. - PMC - PubMed
1. Cao Y., Wei J., Zou L., Jiang T., Wang G., Chen L. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. 2020;146:137–146.e3. - PMC - PubMed
1. Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. - PMC - PubMed
1. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069. - PMC - PubMed
1. Liang W.H., Guan W.J., Li C.C., Li Y.M., Liang H.R., Zhao Y. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China. Eur Respir J. 2020;55 - PMC - PubMed